EUCTR2005-001189-15-GB进行中（未招募）不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Prior to any study-specific procedures being performed, the subject voluntarily signs an Informed Consent Form (ICF)/and any privacy statement/authorization form required by the region in which the subject is participating, after having its contents fully explained and all questions answered. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) must approve the ICFs.
- •2. Subjects must have successfully completed the Phase 3 Study T-EE04-084; and have endoscopically proven healed EE.
- •3. All female subjects must agree to continued use of a double barrier method of birth control. Oral, injectable or patch contraceptives may be used as one method if the subject has been taking them for greater than three months duration at the Screening Visit. Subjects who have had a bilateral tubal ligation, hysterectomy or are post-menopausal (the absence of menses for 1-2 years with a Follicle-Stimulating Hormone [FSH] level >/= 40 IU/L or absence of menses for > 2 years) are not required to use birth control.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any condition that may require surgery during the study.
- •2. Use of prescription or non-prescription PPIs, histamine (H2) receptor antagonists or sucralfate throughout the study.
- •3. Use of antacids [except for study supplied Gelusil (U.S. sites) or a similar equivalent approved antacid (ex U.S. sites)] throughout the study.
- •4. Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study.
- •5. Use of misoprostil or prokinetics throughout the study.
- •6. Need for continuous anticoagulant therapy.
- •7. Evidence of uncontrolled systemic disease.
- •8. Subject who, in the opinion of the investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.
研究者
相似试验
进行中（未招募）
不适用
A Study to Test the Effect and Safety of Brodalumab Compared WithPlacebo and Ustekinumab and the Results of Changing Strength orFrequency of Brodalumab in People with Moderate to Severe PlaquePsoriasis: AMAGINE-3Moderate to severe plaque psoriasisMedDRA version: 15.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-000667-24-ITAMGEN INC.1,800
进行中（未招募）
1 期
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and Ustekinumab and the Results of Changing Strength or Frequency of Brodalumab in People with Moderate to Severe Plaque Psoriasis: AMAGINE-3Moderate to severe plaque psoriasisMedDRA version: 14.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-000667-24-GRAmgen Inc.1,800
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia SyndromeFamilial Chylomicronemia SyndromeMedDRA version: 24.1Level: LLTClassification code 10085051Term: Familial chylomicronemia syndromeSystem Organ Class: 100000004850EUCTR2021-003680-10-IEArrowhead Pharmaceuticals, Inc.60
进行中（未招募）
不适用
Phase III CDK in refractory Cchronic lymphocytic leukemia (CLL)MedDRA version: 14.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2011-005186-20-LVMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.466
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive EsophagitisErosive esophagitisEUCTR2005-001187-31-GBTAP Pharmaceutical Products Inc.1,950